{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=6",
    "query": {
      "intervention": "Placebo film",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 309,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T23:51:05.248Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05199818",
      "title": "Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chemotherapy-induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Palonosetron HCl Buccal Film 0.5 mg",
          "type": "DRUG"
        },
        {
          "name": "IV Palonosetron 0.25 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xiamen LP Pharmaceutical Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2022-03-01",
      "completion_date": "2023-11",
      "has_results": false,
      "last_update_posted_date": "2023-01-20",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 13,
      "location_summary": "Chandler, Arizona • Anaheim, California • Lakeland, Florida + 9 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05199818"
    },
    {
      "nct_id": "NCT03594110",
      "title": "EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6609,
      "start_date": "2019-01-31",
      "completion_date": "2024-07-02",
      "has_results": true,
      "last_update_posted_date": "2025-07-20",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 47,
      "location_summary": "Huntsville, Alabama • Mesa, Arizona • San Diego, California + 38 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03594110"
    },
    {
      "nct_id": "NCT03375320",
      "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Functioning Pancreatic Neuroendocrine Tumor",
        "Intermediate Grade Lung Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Tumor G1",
        "Locally Advanced Lung Neuroendocrine Neoplasm",
        "Locally Advanced Pancreatic Neuroendocrine Tumor",
        "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm",
        "Low Grade Lung Neuroendocrine Neoplasm",
        "Lung Neuroendocrine Tumor",
        "Lung Neuroendocrine Tumor G2",
        "Metastatic Digestive System Neuroendocrine Neoplasm",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Metastatic Lung Neuroendocrine Neoplasm",
        "Metastatic Lung Neuroendocrine Tumor",
        "Metastatic Pancreatic Neuroendocrine Neoplasm",
        "Metastatic Pancreatic Neuroendocrine Tumor",
        "Metastatic Thymus Neuroendocrine Neoplasm",
        "Neuroendocrine Neoplasm",
        "Neuroendocrine Tumor",
        "Neuroendocrine Tumor G2",
        "Non-Functioning Pancreatic Neuroendocrine Tumor",
        "Pancreatic Serotonin-Producing Neuroendocrine Tumor",
        "Thymus Neuroendocrine Tumor",
        "Unresectable Digestive System Neuroendocrine Neoplasm",
        "Unresectable Digestive System Neuroendocrine Tumor G1",
        "Unresectable Lung Neuroendocrine Neoplasm",
        "Unresectable Pancreatic Neuroendocrine Neoplasm",
        "Unresectable Thymus Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2018-10-26",
      "completion_date": "2027-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 432,
      "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03375320"
    },
    {
      "nct_id": "NCT03889639",
      "title": "Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "SAR442168",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 130,
      "start_date": "2019-03-29",
      "completion_date": "2020-01-02",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 9,
      "location_summary": "Cullman, Alabama • Maitland, Florida • Sunrise, Florida + 6 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03889639"
    },
    {
      "nct_id": "NCT05348681",
      "title": "A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "RIST4721",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aristea Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2022-07-18",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05348681"
    },
    {
      "nct_id": "NCT05834738",
      "title": "Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy",
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "Atrasentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2023-07-20",
      "completion_date": "2025-10-29",
      "has_results": true,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Oak Brook",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05834738"
    },
    {
      "nct_id": "NCT04472598",
      "title": "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelofibrosis (MF)"
      ],
      "interventions": [
        {
          "name": "Placebo for Navitoclax",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2020-09-29",
      "completion_date": "2025-01-29",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 35,
      "location_summary": "Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04472598"
    },
    {
      "nct_id": "NCT03277261",
      "title": "Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis (RMS)"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "IV Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 549,
      "start_date": "2017-09-19",
      "completion_date": "2020-11-06",
      "has_results": true,
      "last_update_posted_date": "2021-12-06",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 14,
      "location_summary": "Carlsbad, California • Long Beach, California • Pasadena, California + 11 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03277261"
    },
    {
      "nct_id": "NCT04411641",
      "title": "Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-relapsing Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Tolebrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Tolebrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 1131,
      "start_date": "2020-09-24",
      "completion_date": "2024-08-29",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04411641"
    },
    {
      "nct_id": "NCT07667803",
      "title": "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Weight Management"
      ],
      "interventions": [
        {
          "name": "Elecoglipron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4500,
      "start_date": "2026-06-29",
      "completion_date": "2029-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-11T23:51:05.248Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07667803"
    }
  ]
}